These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Urine dicarboxylic acids change in pre-symptomatic Alzheimer's disease and reflect loss of energy capacity and hippocampal volume. Castor KJ; Shenoi S; Edminster SP; Tran T; King KS; Chui H; Pogoda JM; Fonteh AN; Harrington MG PLoS One; 2020; 15(4):e0231765. PubMed ID: 32298384 [TBL] [Abstract][Full Text] [Related]
7. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease. Yassine HN; Rawat V; Mack WJ; Quinn JF; Yurko-Mauro K; Bailey-Hall E; Aisen PS; Chui HC; Schneider LS Alzheimers Res Ther; 2016 Jun; 8():25. PubMed ID: 27358067 [TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort. Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385 [TBL] [Abstract][Full Text] [Related]
10. Compromised Behavior and Gamma Power During Working Memory in Cognitively Healthy Individuals With Abnormal CSF Amyloid/Tau. Rochart R; Liu Q; Fonteh AN; Harrington MG; Arakaki X Front Aging Neurosci; 2020; 12():574214. PubMed ID: 33192465 [TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer's Disease, But Has Similar Diagnostic Accuracy to Aβ42. Lauridsen C; Sando SB; Møller I; Berge G; Pomary PK; Grøntvedt GR; Salvesen Ø; Bråthen G; White LR Front Aging Neurosci; 2017; 9():210. PubMed ID: 28701950 [TBL] [Abstract][Full Text] [Related]
13. Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data. Guhra M; Thomas C; Boedeker S; Kreisel S; Driessen M; Beblo T; Ohrmann P; Toepper M Exp Gerontol; 2016 Jan; 73():107-13. PubMed ID: 26585048 [TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults. Paternicò D; Galluzzi S; Drago V; Bocchio-Chiavetto L; Zanardini R; Pedrini L; Baronio M; Amicucci G; Frisoni GB Alzheimers Dement; 2012 Nov; 8(6):520-7. PubMed ID: 22677492 [TBL] [Abstract][Full Text] [Related]
15. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Galasko D; Chang L; Motter R; Clark CM; Kaye J; Knopman D; Thomas R; Kholodenko D; Schenk D; Lieberburg I; Miller B; Green R; Basherad R; Kertiles L; Boss MA; Seubert P Arch Neurol; 1998 Jul; 55(7):937-45. PubMed ID: 9678311 [TBL] [Abstract][Full Text] [Related]
16. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration. Höglund K; Kern S; Zettergren A; Börjesson-Hansson A; Zetterberg H; Skoog I; Blennow K Transl Psychiatry; 2017 Jan; 7(1):e995. PubMed ID: 28072416 [TBL] [Abstract][Full Text] [Related]